124 related articles for article (PubMed ID: 38538281)
1. Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma.
Xiang Y; Jia M; Gao Y; Yang F; Wang T; Dai R; Wang M; Miao H
Front Biosci (Landmark Ed); 2024 Mar; 29(3):106. PubMed ID: 38538281
[TBL] [Abstract][Full Text] [Related]
2. α-Tocotrienol and Redox-Silent Analogs of Vitamin E Enhances Bortezomib Sensitivity in Solid Cancer Cells through Modulation of NFE2L1.
Ishii K; Hido M; Sakamura M; Virgona N; Yano T
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298331
[TBL] [Abstract][Full Text] [Related]
3. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
[TBL] [Abstract][Full Text] [Related]
4. Piperlongumine and bortezomib synergically inhibit cholangiocarcinoma via ER stress-induced cell death.
Naradun N; Talabnin K; Ayuttha KIN; Talabnin C
Naunyn Schmiedebergs Arch Pharmacol; 2023 Jan; 396(1):109-120. PubMed ID: 36227332
[TBL] [Abstract][Full Text] [Related]
5. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
6. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
[TBL] [Abstract][Full Text] [Related]
7. Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.
Yu T; Tao Y; Yang M; Chen P; Gao X; Zhang Y; Zhang T; Chen Z; Hou J; Zhang Y; Ruan K; Wang H; Hu R
Cell Res; 2014 Oct; 24(10):1214-30. PubMed ID: 25223703
[TBL] [Abstract][Full Text] [Related]
8. NFE2L1 and NFE2L3 Complementarily Maintain Basal Proteasome Activity in Cancer Cells through CPEB3-Mediated Translational Repression.
Waku T; Katayama H; Hiraoka M; Hatanaka A; Nakamura N; Tanaka Y; Tamura N; Watanabe A; Kobayashi A
Mol Cell Biol; 2020 Jun; 40(14):. PubMed ID: 32366381
[TBL] [Abstract][Full Text] [Related]
9. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
10. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
11. Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1.
Li J; Ma X; Xu F; Yan Y; Chen W
Pharm Biol; 2024 Dec; 62(1):314-325. PubMed ID: 38571483
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD
World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding ribonucleic acid zinc finger E-box binding homeobox 1 antisense RNA 1 regulates myocardial fibrosis in diabetes through the Hippo-Yes-associated protein signaling pathway.
Wu J; Lyu R; Chen S; Wang X
J Diabetes Investig; 2023 Aug; 14(8):940-952. PubMed ID: 37309277
[TBL] [Abstract][Full Text] [Related]
14. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma.
Jiang TY; Pan YF; Wan ZH; Lin YK; Zhu B; Yuan ZG; Ma YH; Shi YY; Zeng TM; Dong LW; Tan YX; Wang HY
Sci Transl Med; 2020 Sep; 12(562):. PubMed ID: 32967970
[TBL] [Abstract][Full Text] [Related]
15. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
[TBL] [Abstract][Full Text] [Related]
16. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
18. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2.
Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z
Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785
[TBL] [Abstract][Full Text] [Related]
19. ZEB1 enhances Warburg effect to facilitate tumorigenesis and metastasis of HCC by transcriptionally activating PFKM.
Zhou Y; Lin F; Wan T; Chen A; Wang H; Jiang B; Zhao W; Liao S; Wang S; Li G; Xu Z; Wang J; Zhang J; Ma H; Lin D; Li Q
Theranostics; 2021; 11(12):5926-5938. PubMed ID: 33897890
[TBL] [Abstract][Full Text] [Related]
20. ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma.
Terashita K; Chuma M; Hatanaka Y; Hatanaka K; Mitsuhashi T; Yokoo H; Ohmura T; Ishizu H; Muraoka S; Nagasaka A; Tsuji T; Yamamoto Y; Kurauchi N; Shimoyama N; Toyoda H; Kumada T; Kaneoka Y; Maeda A; Ogawa K; Natsuizaka M; Kamachi H; Kakisaka T; Kamiyama T; Taketomi A; Matsuno Y; Sakamoto N
J Clin Pathol; 2016 Jul; 69(7):593-9. PubMed ID: 26670746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
